Cryo-electron microscopy structure of the glucagon receptor with a dual-agonist peptide.

G protein–coupled receptor (GPCR) GLP-1 receptor cryo-electron microscopy dual agonist glucagon glucagon receptor glucagon-like peptide-1 receptor metabolic disorder peptide 15 (P15) single particle analysis structural biology structure-function

Journal

The Journal of biological chemistry
ISSN: 1083-351X
Titre abrégé: J Biol Chem
Pays: United States
ID NLM: 2985121R

Informations de publication

Date de publication:
10 07 2020
Historique:
received: 09 04 2020
revised: 30 04 2020
pubmed: 7 5 2020
medline: 14 1 2021
entrez: 7 5 2020
Statut: ppublish

Résumé

Unimolecular dual agonists of the glucagon (GCG) receptor (GCGR) and glucagon-like peptide-1 receptor (GLP-1R) are a new class of drugs that are potentially superior to GLP-1R-specific agonists for the management of metabolic disease. The dual-agonist, peptide 15 (P15), is a glutamic acid 16 analog of GCG with GLP-1 peptide substitutions between amino acids 17 and 24 that has potency equivalent to those of the cognate peptide agonists at the GCGR and GLP-1R. Here, we have used cryo-EM to solve the structure of an active P15-GCGR-G

Identifiants

pubmed: 32371397
pii: S0021-9258(17)48955-1
doi: 10.1074/jbc.RA120.013793
pmc: PMC7363120
doi:

Substances chimiques

GLP1R protein, human 0
Glucagon-Like Peptide-1 Receptor 0
Peptides 0
Receptors, Glucagon 0

Banques de données

PDB
['6LMK', '5VAI']

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

9313-9325

Informations de copyright

© 2020 Chang et al.

Déclaration de conflit d'intérêts

Conflict of interest—The authors declare that they have no conflicts of interest with the contents of this article.

Références

Mol Cell. 2020 Feb 6;77(3):669-680.e4
pubmed: 32004470
Science. 2019 Apr 12;364(6436):148-153
pubmed: 30975883
Nature. 2013 Jul 25;499(7459):444-9
pubmed: 23863937
Nat Methods. 2019 Jun;16(6):471-477
pubmed: 31086343
Mol Cell Endocrinol. 2019 May 15;488:1-13
pubmed: 30930094
Acta Crystallogr D Biol Crystallogr. 2010 Apr;66(Pt 4):486-501
pubmed: 20383002
Acta Crystallogr D Struct Biol. 2019 Oct 1;75(Pt 10):861-877
pubmed: 31588918
Nature. 2017 Jun 8;546(7657):248-253
pubmed: 28538729
J Pept Sci. 2011 Apr;17(4):270-80
pubmed: 21294225
ACS Pharmacol Transl Sci. 2019 Jan 11;2(1):31-51
pubmed: 32219215
Nature. 2018 Sep;561(7724):492-497
pubmed: 30209400
Cell Res. 2020 May;30(5):436-445
pubmed: 32047270
Nat Med. 2015 Jan;21(1):27-36
pubmed: 25485909
Mol Metab. 2013 Dec 14;3(3):241-51
pubmed: 24749050
J Clin Endocrinol Metab. 2020 Mar 1;105(3):
pubmed: 31608926
Chem Rev. 2017 Jan 11;117(1):111-138
pubmed: 27040440
Nature. 2017 Jun 8;546(7657):259-264
pubmed: 28514451
Mol Pharmacol. 2016 Mar;89(3):335-47
pubmed: 26700562
Nat Methods. 2017 Mar;14(3):290-296
pubmed: 28165473
Am J Physiol Endocrinol Metab. 2012 Jul 15;303(2):E265-71
pubmed: 22621866
J Struct Biol. 2016 Jan;193(1):1-12
pubmed: 26592709
Peptides. 2020 Mar;125:170225
pubmed: 31786282
Nature. 2018 Mar 1;555(7694):121-125
pubmed: 29466332
Endocr Rev. 2018 Oct 1;39(5):719-738
pubmed: 29905825
Mol Pharmacol. 2010 Sep;78(3):394-401
pubmed: 20573782
ACS Pharmacol Transl Sci. 2020 Mar 20;3(2):263-284
pubmed: 32296767
Nature. 2017 Jun 1;546(7656):118-123
pubmed: 28437792
Lancet. 2018 Jun 30;391(10140):2607-2618
pubmed: 29945727
Diabetes Obes Metab. 2019 Jan;21(1):120-128
pubmed: 30091218
Diabetes Obes Metab. 2020 Apr;22(4):640-647
pubmed: 31808298
Obesity (Silver Spring). 2012 Aug;20(8):1566-71
pubmed: 22421924
Nature. 2011 Jul 19;477(7366):549-55
pubmed: 21772288
J Comput Chem. 2005 Dec;26(16):1781-802
pubmed: 16222654
J Biol Chem. 2018 Jun 15;293(24):9370-9387
pubmed: 29717000
Diabetes Metab Syndr Obes. 2020 Feb 18;13:433-438
pubmed: 32110076
Mol Cell. 2020 Feb 6;77(3):656-668.e5
pubmed: 32004469
Nat Struct Mol Biol. 2020 Mar;27(3):274-280
pubmed: 32157248
Int Rev Cell Mol Biol. 2016;326:279-341
pubmed: 27572131
Br J Pharmacol. 2001 Aug;133(8):1249-54
pubmed: 11498510
Nat Methods. 2013 Jun;10(6):584-90
pubmed: 23644547
Elife. 2018 Nov 09;7:
pubmed: 30412051
Nat Rev Endocrinol. 2015 Jun;11(6):329-38
pubmed: 25850661
Diabetes Obes Metab. 2018 Feb;20 Suppl 1:22-33
pubmed: 29364586
Nature. 2020 Jan;577(7790):432-436
pubmed: 31915381
Nat Chem Biol. 2009 Oct;5(10):749-57
pubmed: 19597507
Cell. 2016 Jun 16;165(7):1632-1643
pubmed: 27315480
Diabetologia. 2017 Oct;60(10):1851-1861
pubmed: 28733905
Br J Pharmacol. 2019 Dec;176 Suppl 1:S21-S141
pubmed: 31710717
Commun Biol. 2019 Jun 19;2:218
pubmed: 31240256
Nat Methods. 2017 Apr;14(4):331-332
pubmed: 28250466
Proc Natl Acad Sci U S A. 2013 Mar 26;110(13):5211-6
pubmed: 23479653
ACS Pharmacol Transl Sci. 2018 Jul 26;1(1):12-20
pubmed: 32219201
ACS Pharmacol Transl Sci. 2018 Sep 07;1(2):73-83
pubmed: 32219204
Science. 2020 Mar 20;367(6484):1346-1352
pubmed: 32193322

Auteurs

Rulue Chang (R)

School of Pharmacy, Shanghai Medical College, Fudan University, Shanghai, China.

Xin Zhang (X)

Monash Institute of Pharmaceutical Sciences, Drug Discovery Biology, Monash University, Parkville, Victoria, Australia.

Anna Qiao (A)

The CAS Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.
University of Chinese Academy of Sciences, Beijing, China.

Antao Dai (A)

The CAS Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.
The National Center for Drug Screening, Shanghai, China.

Matthew J Belousoff (MJ)

Monash Institute of Pharmaceutical Sciences, Drug Discovery Biology, Monash University, Parkville, Victoria, Australia.

Qiuxiang Tan (Q)

The CAS Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.
University of Chinese Academy of Sciences, Beijing, China.

Lijun Shao (L)

The CAS Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.
University of Chinese Academy of Sciences, Beijing, China.
School of Life Science and Technology, ShanghaiTech University, Shanghai, China.

Li Zhong (L)

The CAS Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.
University of Chinese Academy of Sciences, Beijing, China.

Guangyao Lin (G)

The CAS Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.
University of Chinese Academy of Sciences, Beijing, China.
School of Life Science and Technology, ShanghaiTech University, Shanghai, China.

Yi-Lynn Liang (YL)

Monash Institute of Pharmaceutical Sciences, Drug Discovery Biology, Monash University, Parkville, Victoria, Australia.

Limin Ma (L)

The CAS Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.

Shuo Han (S)

The CAS Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.

Dehua Yang (D)

The CAS Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.
The National Center for Drug Screening, Shanghai, China.

Radostin Danev (R)

Graduate School of Medicine, University of Tokyo, Tokyo, Japan.

Ming-Wei Wang (MW)

School of Pharmacy, Shanghai Medical College, Fudan University, Shanghai, China Patrick.sexton@monash.edu mwwang@simm.ac.cn denise.wootten@monash.edu beiliwu@simm.ac.cn.
The CAS Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.
University of Chinese Academy of Sciences, Beijing, China.
The National Center for Drug Screening, Shanghai, China.
School of Life Science and Technology, ShanghaiTech University, Shanghai, China.

Denise Wootten (D)

Monash Institute of Pharmaceutical Sciences, Drug Discovery Biology, Monash University, Parkville, Victoria, Australia Patrick.sexton@monash.edu mwwang@simm.ac.cn denise.wootten@monash.edu beiliwu@simm.ac.cn.

Beili Wu (B)

The CAS Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China Patrick.sexton@monash.edu mwwang@simm.ac.cn denise.wootten@monash.edu beiliwu@simm.ac.cn.
University of Chinese Academy of Sciences, Beijing, China.
School of Life Science and Technology, ShanghaiTech University, Shanghai, China.

Patrick M Sexton (PM)

Monash Institute of Pharmaceutical Sciences, Drug Discovery Biology, Monash University, Parkville, Victoria, Australia Patrick.sexton@monash.edu mwwang@simm.ac.cn denise.wootten@monash.edu beiliwu@simm.ac.cn.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH